Background. The importance of delivering appropriate therapy to patients at the onset of treatment is well established. However, this goal is easier said than done given the complexity and uniqueness of each patient case. Nonetheless, treatment decisions driven by pharmacokinetic-pharmacodynamic (PK-PD) can account for patient variability and assist in selecting patient-specific therapies. Using data obtained from electronic decision support software (EDSS), we evaluated the relationship between the probability of PK-PD target attainment (PTA) and patient outcomes.
Methods. Data obtained over a 20-month period from an EDSS were evaluated and included: (1) patient demographics; (2) infection type; (3) pathogen; (4) clinician-selected antimicrobials; (4) pathogen susceptibility; (5) clinician-provided early and late outcomes. Data calculated by the EDSS included the PTA for all evaluated antimicrobial regimens. Using logistic regression, relationships between the probability of PTA and clinical improvement and clinical success at 48 hours and Days 7-10, respectively, were assessed.
Results. Data for 121 patient cases with various infection types were available. The most common pathogens reported were MRSA (14.9%) and K. pneumoniae (14. Based on these relationships, the predicted percent probability of a positive outcome at 48 hours and Days 7-10 for an initial treatment regimen with PTA of 90% was 77.2% and 76.1%, respectively.
Conclusion. Statistically significant positive relationships between PTA and clinical outcomes at 48 hours and Days 7-10 were identified. These data demonstrate the value of PK-PD in dosing regimen selection and provide a path toward delivering appropriate initial therapy to optimize patient outcomes. Background. Unbound plasma concentrations of β-lactam antibiotics vary widely and attainment of PK/PD targets is highly variable in critically ill patients, which may affect microbiologic cure or contribute to toxicity. PK/PD-based antibiotic dosing programs may provide more accurate doses that achieve predicted targets for a cultured organism.
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Methods. This was a single center, prospective study of critically ill patients with culture positive gram-negative infections treated with meropenem (MEM) or piperacillin/tazobactam (TZP). A PK/PD-based antibiotic dosing app was used to select doses that had a probability of target attainment (PTA) of 90% or greater for time above MIC (fT >MIC ) of at least 40% for MEM and 50% for TZP. Total meropenem, piperacillin and tazobactam mid-point and trough concentrations were obtained at steady-state and adjusted for protein binding, to assess target attainment.
Results. Thirty-six patients were enrolled; 20 received MEM and 16 TZP. Antibiotic concentrations varied widely amongst patients, particularly with TZP. MEM and TZP concentrations are displayed in Table 1 Conclusion. A PK/PD based antibiotic dosing calculator that provides individualized β-lactam doses can lead to altered doses that may increase probability of target attainment in critically ill patients. Future research is needed to review the relevance of PK/PD-based dose adjustments on clinical outcomes. 
